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Causes of Death in HIV-1–Infected Patients Treated
with Antiretroviral Therapy, 1996–2006: Collaborative
Analysis of 13 HIV Cohort Studies
The Antiretroviral Therapy Cohort Collaborationa
Background. We examined specific causes of mortality in human immunodeficiency virus type 1 (HIV-1)–
infected patients who initiated antiretroviral therapy (ART) in Europe and North America from 1996 through
2006, and we quantified associations of prognostic factors with cause-specific mortality.
Methods. We retrospectively classified all deaths among 39,272 patients enrolled in 13 HIV-1 cohorts (154,667
person years of follow-up) into the categories specified in the Cause of Death (CoDe) project protocol.
Results. In 1597 (85%) of 1876 deaths, a definitive cause of death could be assigned. Among these, 792 deaths
(49.5%) were AIDS related, followed by non-AIDS malignancies (189; 11.8%), non-AIDS infections (131; 8.2%),
violence- and/or drug-related causes (124; 7.7%), liver disease (113; 7.0%), and cardiovascular disease (103; 6.5%).
Rates of AIDS-related death (hazard ratio [HR] per 100 cell decrease, 1.43; 95% confidence interval [CI], 1.34–
1.53) and death from renal failure (HR, 1.73; 95% CI, 1.18–2.55) were strongly inversely related to CD4 count at
initiation of ART, whereas rates of death attributable to AIDS (HR for viral load 15 vs 5 log copies/mL, 1.31;
95% CI, 1.12–1.53), infection (HR, 1.85; 95% CI, 1.25–2.73), cardiovascular (HR, 1.54; 95% CI, 1.05–2.27), and
respiratory causes (HR, 3.62; 95% CI, 1.30–10.09) were higher in patients with baseline viral load 15 log copies/
mL than in other patients. Rates of each cause of death were higher in patients with presumed transmission via
injection drug use than in other patients, with marked increases in rates of liver-related (HR for injection drug
use vs non–injection drug use, 6.06; 95% CI, 4.03–9.09) and respiratory tract–related (HR, 4.94; 95% CI, 1.96–
12.45) mortality. The proportion of deaths classified as AIDS related decreased with increasing duration of ART.
Conclusions. Important contributors to non-AIDS mortality in treated HIV-1–infected individuals must be
addressed if decreases in mortality rates are to continue.
Combination antiretroviral therapy (ART) has dra-
matically improved life expectancy for human immu-
nodeficiency virus type 1 (HIV-1)–infected patients [1],
primarily because of reductions in deaths attributable
to AIDS-related conditions [2]. However, an increasing
number of deaths are attributable to causes not con-
ventionally considered to be HIV-1 related [3]. These
may be related to immunodeficiency and inflammation
attributable to uncontrolled viremia and, thus, may still
be linked to HIV-1 infection [4, 5]. Therefore, large
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clinical end point trials now incorporate non-AIDS
events as end points [6]. With the introduction of more
effective and tolerable ART regimens, it is important
to monitor causes of death and assess associated risk
factors.
Coding systems, such as the World Health Organi-
zation’s International Classification of Diseases, 9th Edi-
tion (ICD-9) [7] and ICD-10 [8], may not reflect recent
rapid changes in our understanding of HIV-1 patho-
genesis. Many AIDS-defining illnesses are poorly iden-
tified in the ICD, and some diseases (eg, central nervous
system diseases) have a different etiology in HIV-1–
infected patients and are, therefore, not covered or are
at risk of misclassification.
We hypothesized that associations of patient char-
acteristics with overall mortality may mask differential
associations with specific causes of death. Using data
on antiretroviral-naive individuals starting ART from a
collaboration of HIV-1 cohorts in high-income coun-
tries, we classified reported deaths using a system de-
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signed for attribution of causes of death in HIV-1–infected
persons. We described frequencies of specific causes of death,
examined associations with prognostic factors at start of ART,
and investigated whether causes of death differ between early
and more recent ART eras and according to duration of time
receiving treatment.
METHODS
Cohorts and patients. The ART Cohort Collaboration was
established in 2000 to estimate prognosis of HIV-1–infected
patients initiating ART in Europe and North America. The
collaboration is described in detail elsewhere [9–11] (http://
www.art-cohort-collaboration.org). Patients naive to ART, aged
116 years, and starting ART with a combination of 3 drugs
were followed. The dataset was assembled during 2007 and
includes patients starting ART during 1996–2006 from 13 co-
horts (Appendix, which appears only on the online version of
the journal). All cohorts had systematic (though different) ap-
proaches to capturing information regarding deaths, predom-
inantly using linkages to death registries or hospital records.
At all sites, institutional review boards approved data collection.
All cohorts provided anonymized data on a predefined set of
demographic, laboratory, and clinical variables, which were
pooled and analyzed centrally.
Coding cause of death. We initially classified deaths into
the 30 categories specified in the Cause of Death (CoDe) project
protocol (http://www.cphiv.dk/). AIDS-related deaths were fur-
ther classified, where possible, as AIDS infection (CoDe 01.1)
or AIDS malignancy (CoDe 01.2). We produced summary ta-
bles with information on each death that included ICD-9, ICD-
10, or free text coding of deaths; patient characteristics at ART
initiation (age, sex, pre-existing AIDS-defining conditions, risk
transmission group); details and timing of new AIDS events
during receipt of treatment; time from treatment initiation to
death; CD4 count obtained closest to death; and whether pa-
tients were receiving ART at time of death. Cause of death for
each patient was classified by a clinician and also was auto-
matically based on ICD codes alone, with use of computer
algorithms developed by the Mortalite´ 2000–2005 Study Group
[12, 13]. Disagreements between clinicians and/or computer-
assigned codes, as well as infrequent causes of death, were in-
dependently examined by pairs of reviewers and, if necessary,
were further discussed by the review panel.
Death was coded as AIDS (CoDe 01) if the patient experi-
enced a serious AIDS-defining condition(s) close to death and/
or had a low CD4 count (!50 cells/mm3) prior to death and
a diagnosis compatible with AIDS as cause of death. Death due
to Hodgkin lymphoma was classified as AIDS related. Deaths
described as due to sepsis/septicemia were coded as bacterial
infection with sepsis (CoDe 2.1.1). Deaths attributed to un-
specified liver failure were classified as hepatitis (CoDe 03) if
the patient was positive for hepatitis C antibody at baseline or
if hepatitis C status was unknown but HIV-1 transmission was
through injection drug use. If the patient was not known to
be an injection drug user or hepatitis C positive, then such
deaths were coded as liver failure (CoDe 14). If a patient was
positive for hepatitis C or B antibodies at baseline and died of
“liver cancer,” we assumed the cancer was secondary to hepatitis
[14]. Deaths described as accidental/violent with a history of
self-harm in ICD-9 were coded as suicide (CoDe 17). If it was
unclear whether death was attributable to suicide, the less spe-
cific code of accidental/violent death (CoDe 16) was assigned.
Deaths described as due to cardiac arrest or respiratory fail-
ure with no other information were coded as unknown (CoDe
92). Deaths due to myocarditis and endocarditis were coded as
non-AIDS infection (CoDe 02). Deaths with insufficient infor-
mation to achieve a consensus were coded as cause unknown
(CoDe 92).
Statistical analyses. We grouped causes associated with
!20 deaths as “other.” For the main analyses, we grouped causes
of death as AIDS (CoDe 01, 01.1, and 01.2), non-AIDS infection
(CoDe 02), liver-related deaths (hepatitis and liver failure
[CoDe 03 and 14]), non-AIDS malignancy (CoDe 04), cardio-
vascular disease (myocardial infarction/ischemic heart disease,
stroke, heart failure/unspecified, and other heart disease [CoDe
08, 09, and 24]), respiratory disease (CoDe 13 and 25), renal
failure (CoDe 15), violent deaths (including accident, suicide,
and overdose [CoDe 16, 17, and 19]), and other. In secondary
analyses we separated deaths due to AIDS into unspecified,
infection, and malignancy; liver disease into hepatitis-related
and other liver disease; cardiovascular disease into myocardial
infarction/ischemic heart disease, stroke, and other heart-re-
lated deaths; and violent deaths into suicide, substance abuse,
and other (including homicide, accident and nonattributed vi-
olent death). We also classified deaths as either AIDS or non-
AIDS related.
Hazard ratios (HRs) for death attributed to all and specific
causes were estimated using multivariable Cox models. In mod-
els for specific causes, patients who died of other causes were
censored at date of death. We estimated cause-specific HR for
the following characteristics measured at start of ART (base-
line): female sex (vs male sex), age (per 10 years), injection
drug user (vs non–injection drug user), prior AIDS diagnosis
(vs no AIDS), CD4 count (per 100 cells/mm3 decrease), and
viral load (HIV-1 RNA level 5 vs !5 log copies/mL). All HRs
were adjusted for these characteristics as well as year of ART
initiation and were stratified by cohort. Linearity of relation-
ships of cause-specific log hazards with age and CD4 count
were assessed using categories of these variables and fractional
polynomials [15]. There was evidence of nonlinearity in the
effect of CD4 count because death rates did not vary greatly
among individuals with baseline CD4 counts 1500 cells/mm3.
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Table 1. Characteristics of 39,272 Patients Included in Analyses at the Start of Anti-
retroviral Therapy (ART), with Follow-up Time and Number of Deaths
Characteristics
Overall, no (%)
of patients
Duration
of follow-up,
person-years
Deaths, no (%)
of patients
Total 39,272 (100) 154,667 1876 (4.8)
Sex
Male 28,487 (73) 115,719 1530 (5.4)
Female 10,785 (27) 38,947 346 (3.2)
Presumed mode of transmission
MSM 14,058 (36) 60,639 539 (3.8)
Heterosexual 16168 (41) 59,115 598 (3.7)
IDU 4987 (13) 20,121 452 (9.1)
Other 4059 (10) 14,909 287 (7.1)
Age, years
16–29 6970 (18) 26,806 163 (2.3)
30–39 16,958 (43) 69,978 716 (4.2)
40–49 10,051 (26) 38,358 542 (5.4)
50 5293 (13) 19,525 455 (8.6)
CDC disease stage
A/B 30,030 (76) 119,019 989 (3.3)
C 9242 (24) 35,648 887 (9.6)
CD4 cell count, cells/mm3
0–99 10,561 (27) 40,825 884 (8.4)
100–199 7883 (20) 28,991 385 (4.9)
200–349 11,544 (29) 42,354 356 (3.1)
350 9284 (24) 42,497 251 (2.7)
HIV-1 RNA, log copies/mL
!4 5205 (13) 20,230 174 (3.4)
4–5 15,708 (40) 63,114 551 (3.5)
5 18,359 (47) 71,322 1151 (6.3)
Year of starting ART
1996–1997 6015 (15) 41,060 526 (8.7)
1998–1999 9696 (25) 53,360 633 (6.5)
2000–2002 12,445 (32) 44,974 509 (4.1)
2003–2006 11,116 (28) 15,272 208 (1.9)
NOTE. CDC, Centers for Disease Control and Prevention; HIV-1, human immunodeficiency virus type
1; IDU, injection drug use; MSM, men who have sex with men.
We therefore replaced baseline CD4 counts that were 1500 cells/
mm3 with 500 cells/mm3, and there was then little evidence of
nonlinearity. We checked for between-cohort heterogeneity in
the association of each risk factor with AIDS- and non–AIDS-
related deaths. There was little evidence of such heterogeneity
(all P values 1.05), except for the effect of viral load on non–
AIDS-related deaths, for which there was weak evidence of
heterogeneity ( ). All subsequent analyses assumed thatPp .04
the effect of risk factors was the same across cohorts. Using
random effects meta-analysis, we estimated the between-cohort
variance in rates of AIDS- and non–AIDS-related deaths to be
0.19 and 0.02, respectively.
We used Poisson regression models to estimate overall and
cause-specific mortality adjusted incidence rate ratios by cal-
endar period of starting ART (1996–1997, 1998–1999, 2000–
2002, 2003–2006) and duration of time receiving ART (!1, 1–
1.99, 2 years) with 1996–1997 and duration of ART !1 year
as reference categories. We estimated cumulative incidence func-
tions for AIDS-related, non–AIDS-related, and unknown deaths
with use of nonparametric modelling that accounts for censoring
because of competing causes of death [16]. These were stacked
to illustrate the contribution of each to total mortality.
RESULTS
Data on 39,272 patients with a median follow-up of 3.6 years
(interquartile range [IQR], 1.6–6.1) were available. Table 1
shows patient characteristics at baseline with corresponding
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Table 2. Frequencies of Specific Causes of
Death According to the Cause of Death (CoDe)
Classification in the 1876 Patients Who Died
This table is available in its entirety in
the online version of Clinical Infectious Diseases
Table 3. Frequencies of Specific Causes of Death in the 1597 Patients Who
Died, with Crude Incidence Rates per 1000 Person-Years of Follow-up
Cause of death
No (%) of patientsa
(n p 1597)
Incidence rate (95% CI)
per 1000 years
AIDS
All 792 (49.6) 5.12 (4.78–5.49)
Nonspecified AIDS 190 (11.9) 1.23 (1.07–1.42)
AIDS infection 366 (22.9) 2.37 (2.14–2.62)
AIDS malignancy 236 (14.8) 1.52 (1.34–1.73)
Non-AIDS malignancy 189 (11.8) 1.22 (1.06–1.41)
Non-AIDS infection 131 (8.2) 0.85 (0.71–1.01)
CVDb
All 126 (7.9) 0.81 (0.68–0.97)
MI/IHD 51 (3.2) 0.33 (0.25–0.43)
Stroke 23 (1.4) 0.15 (0.10–0.22)
Other heart disease 52 (3.3) 0.34 (0.26–0.44)
Violencec
All 124 (7.8) 0.80 (0.67–0.96)
Suicide 48 (3.0) 0.31 (0.23–0.41)
Substance abuse 42 (2.6) 0.41 (0.32–0.52)
Other violent death 34 (2.1) 0.22 (0.16–0.31)
Liver related
All 113 (7.1) 0.73 (0.61–0.88)
Hepatitis related 63 (3.9) 0.41 (0.32–0.52)
Other liver related 50 (3.1) 0.32 (0.25–0.43)
Respiratory disease 25 (1.6) 0.16 (0.11–0.24)
Renal failure 24 (1.5) 0.16 (0.10–0.23)
Other causes with n ! 20 73 (4.6) 0.47 (0.38–0.59)
NOTE. CI, confidence interval; CVD, cardiovascular disease; MI/IHD, myocardial infarction/
ischemic heart disease.
a 39,272 patients with 154,667 years of follow-up.
b CVD includes MI/IHD, stroke, heart failure/unspecified, and other heart disease.
c Violence includes homicide, accident, suicide, and substance abuse, as well as ill-defined
violent deaths.
years of follow-up and numbers of deaths. Median age was 37
years (IQR, 31–44) and median calendar month of initiation
of ART was December 2000 (October 1998–April 2003). The
initial antiretroviral regimen contained 4 drugs (excluding
low-dose ritonavir) in 2264 (6%) and 3 drugs in 37,008 (94%)
patients. A protease inhibitor was used in 24,267 (62%) and a
nonnucleoside reverse-transcriptase inhibitor in 12,688 (32%)
initial regimens.
During 154,667 years of follow-up, 1876 (4.8%) patients
died. Of these deaths, 1597 (85%) were assigned a cause ac-
cording to the CoDe categories. Table 2 shows the number of
deaths in each of these categories. The crude all-cause death
rate was 12.1 deaths per 1000 person-years (95% confidence
interval [CI], 11.6–12.7 deaths per 1000 person-years). Those
who died had lower median CD4 counts at baseline (110 cells/
mm3; IQR, 33–247 cells/mm3) than those who survived (217
cells/mm3; IQR, 94–343 cells/mm3). In those who died, the
median time to death from baseline was 1.8 years (IQR, 0.6–
3.8). Compared with patients with an assigned cause of death,
the 279 patients with unknown cause of death were more likely
to be male, to be an injection drug user, and to have less
advanced HIV-1 disease at baseline. At the last clinic visit before
death, they were more likely to be receiving treatment and had
higher median CD4 counts (215 vs 110 cells/mm3).
Table 3 shows frequencies of the 8 grouped causes of death.
Seven hundred ninety-two (49.6%) of the deaths for which a
cause was assigned were due to AIDS, of which 366 (46.2%)
could be further classified as infection and 236 (29.8%) as
malignancy. The most frequent non-AIDS causes of death were
non-AIDS malignancy (11.8%), non-AIDS infection (8.2%),
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Table 4. Frequencies of Specific Causes of
Death in the 1597 Patients Who Died by Year
of Death
This table is available in its entirety in
the online version of Clinical Infectious Diseases
Figure 1. Adjusted hazard ratios (HRs) and 95% confidence intervals of risk factors at start of antiretroviral therapy for specific causes of death
from Cox models with CD4 cell count (per 100 cell decrease), transmission risk group (injection drug user [IDU] vs non-IDU), viral load (human
immunodeficiency virus type 1 RNA load 5 vs !5 log copies/mL), and prior AIDS diagnosis (vs no AIDS). Models were mutually adjusted for age,
sex, IDU, CD4 count, viral load, prior AIDS diagnosis, cohort, and year of starting antiretroviral therapy. CVD, cardiovascular disease.
cardiovascular disease (7.9%, of which 40% were myocardial
infarction/ischemic heart disease and 18% stroke), violence
(7.8%, approximately one-third each of suicide, substance
abuse, and homicide/accident/unspecified), and liver disease
(7.1%, of which 55.8% were hepatitis related). The most fre-
quent sites for non-AIDS malignancies were respiratory tract
or intrathoracic organs (36.7%); digestive organs and perito-
neum (28.7%); lip, oral cavity, and pharynx (6.0%); and skin
(4.7%). During the first year of ART, 63% of deaths were at-
tributable to AIDS; this subsequently decreased to 43%. Table
3 shows crude incidence rates per 1000 years of different causes
of death; note that these are underestimates because 15% of
deaths could not be classified. Table 4 shows frequencies of
cause-specific death by year of death. The proportion of AIDS-
related deaths decreased from 58.5% in 1996–1999 to 43.7%
in 2003–2006. The proportion of deaths due to AIDS-defining
cancers decreased from 20.5% to 12.5%, and the proportion
of deaths due to non–AIDS-defining cancers increased from
7.3% to 15.4% over the same time periods.
Figure 1 shows adjusted HRs for the association of prognostic
factors at baseline with specific causes of death. Lower CD4
counts were associated with higher rates of deaths due to AIDS,
non-AIDS malignancy, renal failure, and other causes, as well
as with death due to AIDS infection (HR per 100 cell decrease,
1.69; 95% CI, 1.52–1.88) but not AIDS malignancies (HR, 1.05;
95% CI, 0.95–1.17). Higher baseline CD4 counts were asso-
ciated with higher rates of death due to violent causes. Rates
of all specific causes of death except renal failure were higher
in injection drug users, with particularly strong associations for
liver-related death, respiratory, death, violent death, and death
due to infection. AIDS before baseline was associated with
higher subsequent rates of death due to both AIDS and non-
AIDS infections. Patients with higher baseline viral load had
higher rates of death due to AIDS, non-AIDS infection, car-
diovascular disease, and respiratory disease.
Table 5 gives further information on associations of prog-
nostic factors with specific causes of death. Older age was
strongly associated with increased rates of non-AIDS malig-
nancy (HR per 10 years, 2.32; 95% CI, 2.04–2.63) and cardio-
vascular disease (HR per 10 years, 2.05; 95% CI, 1.76–2.39).
The cause of death least strongly associated with age was AIDS
(HR per 10 years, 1.19; 95% CI, 1.11–1.28). There was a marked
increase in rates of renal death in patients aged 160 years.
Compared with male patients, female patients had lower rates
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Table 5. Mutually Adjusted Hazard Ratios for
Specific Causes of Death (Frequency, 120%) for
Risk Factors at Start of Antiretroviral Therapy
(ART), from Multivariable Cox Models Stratified
by Cohort and Calendar Year of Starting ART
This table is available in its entirety in
the online version of Clinical Infectious Diseases
Figure 2. Bar graph showing crude cause-specific mortality rate according to length of time since start of combination antiretroviral therapy (cART).
CVD, cardiovascular disease.
of all-cause mortality (HR, 0.84; 95% CI, 0.74–0.94) and, in
particular, lower rates of death due to AIDS malignancies (HR,
0.58; 95% CI, 0.40–0.84) and non-AIDS malignancies (HR,
0.50; 95% CI, 0.31–0.79).
Figure 2 displays cause-specific mortality rates according to
time since starting ART. Rates of death due to AIDS, non-AIDS
infection, and renal failure decreased markedly with increasing
time receiving ART. Table 6 shows cause-specific mortality in-
cidence rate ratios according to duration of ART and calendar
year of starting ART, adjusted for prognostic factors. Rates of
AIDS-related mortality decreased with both time on ART (P !
, by test for trend) and with year of starting ART ( )..001 P ! .001
Rates of death due to non-AIDS infection and renal failure also
decreased with time receiving ART.
Figure 3 (upper panel) shows cumulative incidence for AIDS-
related, non-AIDS-related, and unknown deaths. The majority
of deaths during the first year of receiving ART were AIDS
related, but because rates of AIDS-related death decrease with
time receiving ART, the cumulative incidence of non–AIDS-
related deaths exceeded that of AIDS-related deaths after ∼4
years of ART. Figure 3 (lower panel) shows that the total cu-
mulative mortality at 8 years was ∼9%, with !4% of deaths
classified as AIDS related.
DISCUSSION
We retrospectively assigned a cause of death for 85% of the
1876 deaths among nearly 40,000 individuals who started ART
during 1996–2006 in Europe and North America. Rates of
AIDS, the leading cause of death, decreased with time receiving
ART, although because time receiving ART is equivalent to
follow-up time, no causal effect of time receiving ART can be
inferred. However, there was little variation in rates of non-
AIDS causes of deaths with year of starting ART and time
receiving ART. Immunodeficiency was associated with death
due to AIDS, non-AIDS malignancy, and renal failure. Rates
of death due to AIDS, non-AIDS infection, cardiovascular dis-
ease, and respiratory disease were higher in patients with base-
line viral loads 15 log copies/mL. Those infected through in-
jection drug use had higher rates of all specific causes of death,
with particularly high rates of liver-related and violent death.
Associations with risk factors could only be analyzed for
frequent causes of death, reflecting the success of ART in re-
ducing overall mortality. We used the CoDe system, which is
specifically designed for classifying causes of death in HIV-1–
infected persons [12]. However, deaths were classified retro-
spectively without complete clinical histories. Classifications
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Figure 3. Cumulative incidence of AIDS-related, non–AIDS-related,
and unknown deaths (upper panel) and total cumulative mortality parti-
tioned by cause of death (lower panel).
may differ from those that would be assigned if full documen-
tation was available. We may have grouped diseases with dif-
ferent etiologies; for example, deaths from myocardial infarc-
tion/ischemic heart disease, stroke, and the more-general
unspecified heart-related deaths. It is likely that some deaths
coded as unspecified heart-related were due to dysrhythmias,
possibly attributable to drug overdose, which would be better
classified as violent death. We may have inappropriately as-
signed some causes of death to AIDS in patients with extremely
low CD4 counts and multiple AIDS conditions but a nonspe-
cific cause of death, such as respiratory failure or coma. None-
theless, the majority of deaths are likely to have been classified
accurately, and misclassifications are unlikely to be associated
with risk factors such as age or time since initiation of ART.
There was some evidence of between-cohort heterogeneity in
death rates, particularly for AIDS-related deaths. Such hetero-
geneity could be attributable to differences in patient charac-
teristics beyond those included in existing models (eg, socio-
economic status) or to underascertainment of deaths in some
cohorts.
Non–HIV-1 markers of disease risk, such as hypertension,
smoking, and alcohol misuse, may be strongly associated with
non-AIDS morbidity and mortality but were not available to
us. We did not analyze associations of ART regimen with mor-
tality because of the likelihood of unmeasured confounding by
indication. Associations of baseline CD4 count with cause-spe-
cific mortality should be interpreted with caution because CD4
count prior to death was used in assigning the cause of death.
Six deaths in injection drug users without direct evidence of
hepatitis C infection were classified as hepatitis related, which
will have increased the estimated association of injection drug
use with hepatitis-related liver disease. However, rates of liver-
related death are 6 times higher in injection drug users, possibly
because of drug dependency, alcohol abuse, or coinfection with
hepatitis.
AIDS opportunistic infections have been reported to be the
most frequent cause of death in the early ART era [17]. Reported
proportions of AIDS-related deaths in the ART era range from
31% (D:A:D collaboration) [18], 40% in Spain [19] and Aus-
tralia [20], 46% in the United Kingdom [21], to 50% in the
United States [22]. Because patients with nonassigned causes
of death had less advanced HIV-1 disease, the proportion of
AIDS-defining deaths is somewhat overestimated in our study.
Among HIV-1–infected adults in France, the proportion of
AIDS-related deaths decreased from 47% to 36% between 2000
and 2005, and the proportion of deaths due to cancer not
related to AIDS or hepatitis increased from 11% to 17% [13,
23]. Compared with our study, the higher proportion of liver-
related disease in France (13%–15%) [13] and the D:A:D
collaboration (15%) [18] may be attributable to a higher pro-
portion of injection drug users.
Acute renal failure remains prevalent among hospitalized
patients with HIV-1 and is associated with increased mortality
in the ART era [24]. Patterns of death due to renal failure were
similar to those due to AIDS, with a strong inverse association
with CD4 count and a decrease associated with time receiving
ART. The same pattern has been described for HIV-1–associated
nephropathy, which is caused by viral replication within the
kidney and associated with end-stage renal disease [25]. Alter-
natively, renal failure can be linked to HIV-1 through shared
risk factors such as hepatitis C [26], antiretroviral drugs (par-
ticularly indinavir and tenofovir), or nephrotoxic drugs used
to treat opportunistic infections.
Ongoing HIV-1 replication is associated with an excess risk
of opportunistic disease and death, even after allowing for CD4
count [27]. In our study, death rates due to infections, as well
as respiratory tract and cardiovascular disease, were associated
with baseline viral loads 15 log copies/mL but not with lower
CD4 counts. Systemic immune activation secondary to high viral
replication, rather than or additional to immunodeficiency, may
promote deaths due to infectious and cardiovascular causes. Sev-
eral infections, including herpes simplex [28], hepatitis C [29],
and tuberculosis [30], have been shown to induce HIV-1 viremia
and worsen outcomes.
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ART continues to dramatically reduce rates of mortality at-
tributable to HIV-1 infection in high-income countries. Lower
rates of deaths due to AIDS after the year 2000 may result from
newer ART regimens having better potency and tolerability.
However, AIDS remains the most common cause of death,
particularly early after initiation of treatment. The strong in-
verse association of rates of death due to AIDS with CD4 counts
at the time of starting ART supports arguments for earlier
initiation of ART [31–33]. Conditions associated with social
and lifestyle factors contribute the next most frequent causes
of death, with violence and liver-related diseases (mainly due
to hepatitis) contributing 15% of all deaths. The importance
of lifestyle is reinforced by the observation that the most com-
mon non-AIDS malignancy reported was lung cancer, likely
associated with smoking. Many endocarditis cases occurred in
patients infected with HIV-1 via injection drug use, who likely
acquired endocarditis through injection drug use. Increases in
rates of deaths due to causes associated with aging, such as
non-AIDS malignancies and cardiovascular disease, imply that
the process of aging will become a dominant factor in HIV-1
mortality in the next decade. Interventions to address risk fac-
tors for lifestyle-related causes of death, as well as monitoring
for and care of diseases associated with old age, will be neces-
sary if the full benefit of ART in decreasing mortality is to
continue in the second decade of ART.
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